Clarapath Acquires Crosscope and Combines Tissue Processing Robotics with AI Powered Digital Pathology for Building the Lab of the Future

Clarapath, a robotics company aimed at catalyzing change in the way pathology laboratories process human and animal tissue, announced the acquisition of Mountain View, CA-based Crosscope. Crosscope is a digital pathology company with a turnkey imaging solution providing best-in-class workflow tools and slide management along with artificial intelligence (AI) and machine learning (ML) technology to assist pathologists with better and faster decision-making.

Recommended AI News: Mavenir Announces Business Communications Portfolio

The enhanced and integrated technologies add a new dimension for laboratory leaders and clinicians. The acquisition combines Clarapath’s SectionStar, the first, fully automated, all-in-one tissue sectioning and transfer system with Crosscope’s workflow and computational pathology tools enabling labs to deliver care faster, more cost effectively, and at higher quality.

“Clarapath is thrilled to welcome Crosscope to the Clarapath team. We believe that the combination of SectionStar’s exceptional automated robotics with Crosscope’s advanced workflow and computational pathology tools provide an end-to-end platform for more patient-centric care in human and animal health,” said Eric Feinstein, CEO of Clarapath. “Our combined offering will solve some of the most pressing issues in the lab such as labor shortages, quality control challenges, and the rapidly increasing volume of samples needing review. We are equally excited about the global expansion of our engineering team in Bombay, India.”

Recommended AI News: T-Mobile Magenta Drive for BMW Powers America’s First 5G Connected Cars

The Crosscope Dx software platform has been designed by pathologists, and aims to streamline the pathology process by enabling interoperability, storage, image management, and collaboration. The software provides end-to-end digital pathology, and advanced, integrated, and highly flexible workflow features with an open and scalable architecture.

The acquisition includes a highly talented team with experience in AI, pathology, and medical software development that will join the Clarapath organization. Added Dr. Jayendra Shinde, Co-Founder and CEO of Crosscope, “We are looking forward to what this combination represents as a new era for pathology, building a true fully-automated, digital, anatomic pathology laboratory solution.”

Recommended AI News: Titaniam Announces Completion of Product Suite to Push Back on the Ransomware Problem

[To share your insights with us, please write to sghosh@martechseries.com]